8 1 Glaucoma “duet”: a single molecule designed to target neuroinflammation (that causes optic neuropathy) and elevated IOP simultaneously B i o p o l y m e r w i t h t w o s m a l l m o l e c u l e s ( “ B C D ” ) Glaucoma “Duet” Neuroprotective Reduces IOP Durable Safe ABCD Platform for Extended Durability High molecular weight to increase ocular half-life, providing potential for a quarterly dosed intravitreal therapy Disease Modifying NLRP3 Inhibitor Targets the NLRP3 inflammasome complex that drives neuroinflammation causing optic neuropathy IOP Lowering Small Molecule Addresses the IOP elevation stressor; NLRP3 inhibitor demonstrates potential to provide additional IOP reduction effects + + + Administered via intravitreal injection 4 key attributes needed in a next generation glaucoma therapy Favorable Safety Demonstrated Zenkuda and the ABCD platform demonstrated a favorable safety profile across multiple pivotal studies (>13,000 intravitreal injections)